TYRA on Nasdaq

Tyra Biosciences, Inc.

American pharmaceutical preparations company based in Carlsbad. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerTYRA on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersCarlsbad, California1
  • Incorporated inDE2
  • Business address2656 State Street, Carlsbad, Ca 920082
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income34567-$132.8M in 2025+1328% since 2020
-$150.0M-$100.0M-$50.0M02020: -$9.3M-$9.3M20202021: -$26.3M-$26.3M2021+183%2022: -$58.9M-$58.9M2022+124%2023: -$79.9M-$79.9M2023+36%2024: -$104.2M-$104.2M2024+30%2025: -$132.8M-$132.8M2025+27%
Net income34567-$119.9M in 2025+1185% since 2020
-$150.0M-$100.0M-$50.0M02020: -$9.3M-$9.3M20202021: -$26.3M-$26.3M2021+182%2022: -$55.3M-$55.3M2022+110%2023: -$69.1M-$69.1M2023+25%2024: -$86.5M-$86.5M2024+25%2025: -$119.9M-$119.9M2025+39%

Every line of the income statement as filed: the last 2 fiscal years, latest first.7

Period ending2025-12-312024-12-31
Research and development$102.9M$80.1M
General and administrative$29.8M$24.1M
Total operating expenses$132.8M$104.2M
Loss from operations-$132.8M-$104.2M
Interest and other income, net$12.8M$17.7M
Total other income$12.8M$17.7M
Net loss-$119.9M-$86.5M
Unrealized gain (loss) on marketable securities available-for-sale, net-$377.0K$389.0K
Comprehensive loss-$120.3M-$86.1M
Net loss per share, basic-$2.01-$1.51
Net loss per share, diluted-$2.01-$1.51
Weighted-average shares used to compute net loss per share - basic59.6M shares57.2M shares
Weighted-average shares used to compute net loss per share - diluted59.6M shares57.2M shares

Compare Tyra Biosciences, Inc. with another company

Leadership

Who has led Tyra Biosciences, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Todd Harris2021–now

President

  1. Todd Harris2023–now

Chief financial officer

  1. Alan Fuhrman2023–now

Chief operating officer

  1. Daniel Bensen2021–2025
  2. Bhavesh Ashar2025–now
2025
Board members and other officers (24)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerHiroomi Tada, M.D., Ph.D. named Feb 13, 202437
  • Executive Officer, DirectorTodd Harris, Ph.D. named Feb 13, 202437
  • DirectorGilla Kaplan, Ph.D. named Feb 13, 202437
  • DirectorJake Simson, Ph.D. named Feb 13, 202437
  • DirectorMelissa McCracken, Ph.D. named Feb 13, 202437
  • DirectorSid Subramony, Ph.D. named Feb 13, 202437

Timeline

  1. Sep 14, 2021New chief executive Todd Harris becomes CEO10

Filings

368 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 45 major events, 171 insider forms, 49 large holders, 1 private raises, 82 other. The latest 20:

  1. Sep 21, 2026SCHEDULE 13G EDGAR
  2. Sep 17, 2026SCHEDULE 13D/A EDGAR
  3. Sep 17, 20264 EDGAR
  4. Sep 17, 20264 EDGAR
  5. Sep 17, 20264 EDGAR
  6. Sep 17, 20264 EDGAR
  7. Sep 17, 2026SCHEDULE 13G EDGAR
  8. Sep 15, 20268-K EDGAR
  9. Sep 15, 2026424B5 EDGAR
  10. Sep 14, 2026FWP EDGAR
  11. Sep 14, 2026S-3ASR EDGAR
  12. Sep 11, 20264 EDGAR
  13. Sep 9, 20268-K EDGAR
  14. Aug 14, 2026SCHEDULE 13G/A EDGAR
  15. Aug 14, 2026SCHEDULE 13G/A EDGAR
  16. Aug 4, 2026424B5 EDGAR
  17. Aug 4, 202610-Q EDGAR
  18. Aug 4, 20268-K EDGAR
  19. Jul 30, 2026SCHEDULE 13G EDGAR
  20. Jun 26, 2026144 EDGAR

The 368 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

112 open-market trades by officers, directors and large owners since October 2021: 10 buys and 102 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 9, 2026Verjee RehanDirectorBuy972$20.58$20.0KForm 4
Mar 25, 2026KAPLAN GILLADirectorSale14,295$36.97$528.5KForm 4
Feb 12, 2026Bensen DanielChief Discovery OfficerSale8,000$32.87$263.0KForm 4
Jan 12, 2026Bensen DanielChief Discovery OfficerSale8,000$28.52$228.2KForm 4
Dec 19, 2025MORE ROBERT JDirectorSale10,000$25.00$250.0KForm 4
Dec 12, 2025Bensen DanielChief Discovery OfficerSale8,000$22.64$181.1KForm 4
Nov 21, 2025MORE ROBERT JDirectorSale246,871$20.25$5.0MForm 4
Nov 19, 2025Bensen DanielChief Discovery OfficerSale49,956$16.32$815.3KForm 4
Nov 18, 2025Bensen DanielChief Discovery OfficerSale75,633$16.07$1.2MForm 4
Nov 17, 2025Bensen DanielChief Discovery OfficerSale20,072$16.18$324.8KForm 4
Nov 14, 2025Bensen DanielChief Discovery OfficerSale110,228$16.02$1.8MForm 4
Nov 13, 2025Bensen DanielChief Discovery OfficerSale1,111$16.00$17.8KForm 4
Jun 18, 2025KAPLAN GILLADirectorSale9,568$9.78$93.6KForm 4
Jun 17, 2025KAPLAN GILLADirectorSale10$10.35$104Form 4
Jun 16, 2025RA CAPITAL MANAGEMENT, L.P.DirectorBuy11,813$10.13$119.7KForm 4
Jun 16, 2025KAPLAN GILLADirectorSale6,814$10.38$70.7KForm 4
Jun 13, 2025RA CAPITAL MANAGEMENT, L.P.DirectorBuy120,167$10.20$1.2MForm 4
Jun 13, 2025KAPLAN GILLADirectorSale15,000$10.31$154.7KForm 4
Jun 12, 2025RA CAPITAL MANAGEMENT, L.P.DirectorBuy31,307$10.20$319.3KForm 4
Jun 12, 2025KAPLAN GILLADirectorSale30,000$10.31$309.3KForm 4

All 112 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Feb 6, 2024Raised $200 million in a private offering of equity Form D: 21 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Ra Capital Management, L.P.12,198,625$389.6M3.4%No change
Fmr LLC8,920,513$284.9M0.0%+1,172,865
Jupiter Topco LLC4,352,448$139.2M0.1%New
Alta Partners Management Company, L.P.3,823,425$122.1M95.9%No change
Nextech Invest Ltd.3,553,585$113.5M5.4%−502,276
TCG Crossover Management, LLC3,248,980$103.8M2.5%No change
BlackRock, Inc.3,031,972$96.8M0.0%+814,043
State Street Corp2,140,368$68.4M0.0%+924,290
Commodore Capital LP1,875,000$59.9M3.6%−600,000
Paradigm Biocapital Advisors LP1,828,607$58.4M1.1%−226,384
Vanguard Capital Management LLC1,508,447$48.2M0.0%+382,477
Bvf Inc/il1,476,196$47.1M1.2%−500,000
5AM Venture Management, LLC1,029,298$32.9M11.4%No change
Deerfield Management Company, L.P.1,017,000$32.5M0.4%+468,000
Hood River Capital Management LLC1,016,775$32.5M0.2%New
Geode Capital Management, LLC970,734$31.0M0.0%+312,252
Caligan Partners LP806,986$25.8M1.2%−469,982
Canaan Partners XI LLC750,000$24.0M18.8%No change
Siren, L.L.C.725,000$23.2M0.5%New
Sio Capital Management, LLC695,315$22.2M3.8%+89,876
Stempoint Capital LP632,754$20.2M3.5%+246,400
Marshall Wace, Llp583,133$18.6M0.0%+385,385
Goldman Sachs Group Inc463,477$14.8M0.0%−86,857
Jennison Associates LLC450,964$14.4M0.0%−181,468
Two Sigma Investments, LP449,808$14.4M0.0%+348,190

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54